Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pierre Conan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification d'inhibiteurs de la Cystathionine-β-Synthase, une enzyme dont la surexpression est impliquée dans la déficience intellectuelle dans la trisomie 21

    by Pierre Conan

    La trisomie 21 est une maladie génétique causée par la présence d’un chromosome 21 supplémentaire. Les patients souffrent d’une dysmorphie crâniofaciale, une cardiomyopathie et un risque accru de développer la maladie d’Alzheimer. À cela s’ajoute une déficience intellectuelle, de gravité variable suivant les patients, pour laquelle il n’existe à ce jour aucun traitement pharmacologique. De nombreuses études se sont concentrées sur l’identification des gènes dont la triplication est impliquée dans la déficience intellectuelle afin de pouvoir développer un traitement pharmacologique. Ces études ont identifié deux gènes en particulier, localisés sur le chromosome 21 : DYRK1A, codant une tyrosine kinase régulant de nombreuses voies de signalisation, et CBS, codant la Cystathionine-Beta- Synthase, responsable de la métabolisation des acides aminés soufrés et de la production d’H2S, un gazotransmetteur important pour la transmission synaptique.Mon projet de thèse consiste à identifier des candidats-médicaments capables de diminuer l’activité enzymatique de CBS. J’ai ainsi identifié deux familles de molécules prometteuses qui ont en commun une grande affinité pour les ions métalliques. De plus, nous avons caractérisé le lien génétique entre l’activité de DYRK1A et CBS. Une meilleure compréhension de la relation existant entre ces deux enzymes devrait permettre d’identifier de nouvelles stratégies thérapeutiques pour traiter la déficience intellectuelle dans la trisomie 21.

  • Open Access

    Cellular Functional Analyses of ARX Variants Reveal New Insights Into Genotype–Phenotype Correlations in Neurodevelopmental Disorders Among Male and Female Patients

    by Rasha Faraj, Audrey Farrugia, Anna C. E. Hurst, Pierre Conan, Jennifer Martin, Audrey Schalk, Sylvia Redon, Aline Dubos, Mathilde Gras, Aurore Curie, et al.

    Neurodevelopmental disorders (NDDs) encompass a wide range of conditions often linked to genetic causes, with mutations in the X‐linked ARX gene representing a recurrent contributor. ARX encodes a transcription factor critical for GABAergic neuron development and functioning, regulating the expression of key neurodevelopmental target genes. Variants in ARX result in a wide clinical spectrum, ranging from asymptomatic female carriers to severe developmental syndromes in both sexes. This study investigates the functional impact of 16 ARX variants, including known pathogenic, likely pathogenic, and novel de novo variants, some associated with atypical presentations such as sudden infant death. Using transient expression in N2a neuroblastoma cells, we employed a comprehensive functional approach—including luciferase reporter assays, Western blotting, immunofluorescence, and RT‐qPCR—to assess protein expression levels, subcellular localization, their interaction with known corepressors (TLE1 and CtBP1), and their transcriptional activity on selected ARX ‐known targets. Our results demonstrate that all tested variants disrupt normal ARX transcriptional function, with several also altering protein localization or expression. Remarkably, a subset of variants exhibited dominant‐negative effects, offering a compelling explanation for unexpectedly severe phenotypes in female patients, likely exacerbated by skewed X‐inactivation and other modifying factors. By integrating experimental data with a literature‐based review of published ARX variants, we provide refined genotype–phenotype correlations, highlighting the importance of mutation type, positional context within key ARX functional domains, and patient sex. Altogether, this study advances our understanding of the molecular mechanisms driving ARX ‐related NDDs, emphasizing the importance of functional testing for accurate variant interpretation and paving the way toward informed genetic counseling and potential therapeutic development.

  • Open Access

    Anti-prion drugs reduce endoplasmic reticulum stress and protect human dopaminergic neurons from death

    by Lucile Gentile, Adeel Nasir, Loane Simon, Anaëlle Timoner, Anaïs Péron, Maha Sinane, Pierre Conan, Alexis Boulinguiez, Anna-Katharina Ückert, Marcel Leist, et al.


  • Open Access

    Identification of 8-Hydroxyquinoline Derivatives That Decrease Cystathionine Beta Synthase (CBS) Activity

    by Pierre Conan, Alice Léon, Mathilde Gourdel, Claire Rollet, Loubna Chaïr, Noéline Caroff, Nelig Le Goux, Catherine Le Jossic-Corcos, Maha Sinane, Lucile Gentile, et al.

    CBS encodes a pyridoxal 5′-phosphate-dependent enzyme that catalyses the condensation of homocysteine and serine to form cystathionine. Due to its implication in some cancers and in the cognitive pathophysiology of Down syndrome, the identification of pharmacological inhibitors of this enzyme is urgently required. However, thus far, attempts to identify such molecules have only led to the identification of compounds with low potency and limited selectivity. We consequently developed an original, yeast-based screening method that identified three FDA-approved drugs of the 8-hydroxyquinoline family: clioquinol, chloroxine and nitroxoline. These molecules reduce CBS enzymatic activity in different cellular models, proving that the molecular mechanisms involved in yeast phenotypic rescue are conserved in mammalian cells. A combination of genetic and chemical biology approaches also revealed the importance of copper and zinc intracellular levels in the regulation of CBS enzymatic activity—copper promoting CBS activity and zinc inhibiting its activity. Taken together, these results indicate that our effective screening approach identified three new potent CBS inhibitors and provides new findings for the regulation of CBS activity, which is crucial to develop new therapies for CBS-related human disorders.